Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
